title: Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals.
abstract: OBJECTIVE
  Small intestine-derived chylomicrons and chylomicron remnants, which are predominant in patients with postprandial hypertriglyceridemia, chylomicron syndrome and/or familial dyslipidemia, carry one molecule of apolipoprotein B-48(apo B-48) per lipoprotein particle. We investigated the reference interval for the apo B-48 concentration.
  
  
  METHODS
  We studied 516 individuals who provided written informed consent and confirmed that they were not taking any medications. BMI, waist circumference, blood pressure and the fasting serum concentrations of LDL-C, triglyceride(TG), HDL-C and apo B-48 were measured. The Apo B-48 concentrations were compared according to sex, a pre- or postmenopausal status, dyslipidemia(LDL-C ≥140 mg/dL, TG ≥150 mg/dL, HDL-C ＜40 mg/dL), metabolic syndrome(MetS) and the number of risk factors.
  
  
  RESULTS
  The fasting apo B-48 concentrations(mean±SD) were significantly higher in men than in women(3.8±3.3 μg/mL vs 2.4±1.9 μg/mL, p＜0.001), subjects with a BMI of ≥25 kg/m(2) versus a BMI of ＜25 kg/m(2) (4.4±3.7 μg/mL vs 2.8±2.4 μg/mL, p＜0.001) and those with versus without MetS(6.5±4.3 μg/mL vs 3.0±2.6 μg/mL, p＜0.001). High apo B-48 concentrations were also observed in correlation with the number of risk factors for the MetS. The upper reference limit of apo B-48 was estimated to be 5.7 μg/mL among the 332 patients with normolipidemia, excluding those exhibiting a mean value above ±2.58 standard deviations(SDs), as the mean and range of mean ±1.96 SD were calculated to be 2.04 μg/mL(reference value) and 0.74 to 5.65 μg/mL(reference interval), respectively.
  
  
  CONCLUSIONS
  Based on our study of normolipidemic patients, the upper reference limit for the fasting apo B-48 concentration is estimated to be 5.7 μg/mL.
authors.affiliation: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
authors.forename: Daisaku
authors.initials: D
authors.lastname: Masuda
authors.forename: Makoto
authors.initials: M
authors.lastname: Nishida
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Arai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hanada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Keiko
authors.initials: K
authors.lastname: Yamauchi-Takihara
authors.forename: Toshiki
authors.initials: T
authors.lastname: Moriyama
authors.forename: Norio
authors.initials: N
authors.lastname: Tada
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
mesh_terms: D000368:Aged; D053283:Apolipoprotein B-48 / Q000097:blood*; D044466:Asian People; D001794:Blood Pressure; D015992:Body Mass Index; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000097:blood / Q000378:metabolism; D005215:Fasting; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood; D008875:Middle Aged; D017698:Postmenopause; D019518:Postprandial Period; D017697:Premenopause; D012016:Reference Values; D012307:Risk Factors
chemical_list: D053283:Apolipoprotein B-48